BIOKOSMOS MEDICAL SCIENTIFIC EQUIPMENT COMMERCIAL INDUSTRY SOCIETE ANONYME, (BIOKOSMOS SA, a pioneering Greek company in the field of radiopharmaceuticals and molecular imaging, brings decades of expertise, advanced technological infrastructure, and strong research capacity to the IFIGENEIA project. With a long-standing commitment to innovation in oncology and nuclear medicine, the company plays a key role in shaping safe and efficient laboratory conditions for isotope production.
BIOKOSMOS S.A. was established in November 1992 with the aim of fully addressing the needs of the Greek medical community in the fields of Oncology and Nuclear Medicine through the provision of high-level services. In 2000, the company marked a turning point by launching the largest advanced-technology investment ever made in Greece in molecular nuclear imaging, including the installation of the country’s first cyclotron for the production of short-lived radioisotopes and radiopharmaceuticals. This strategic step established BIOKOSMOS S.A. as a leading force in the sector and contributed decisively to the autonomy and self-sufficiency of Greece in advanced imaging medicine. Following more than three years of intensive research and development, carried out in close cooperation with academic institutions, internationally recognised scientists, highly specialised technical experts, and relevant authorities, the investment became fully operational.
Since 2004, BIOKOSMOS S.A. has been producing radiopharmaceuticals for PET/CT examinations in its state-of-the-art facilities, which are considered a reference point by the European radiopharmaceutical community and are frequently visited by researchers, trainees, and postgraduate students. The company holds all necessary licenses for the production, distribution, and transportation of radiolabelled compounds and radiopharmaceuticals, as well as a GMP certificate, issued by the Greek Atomic Energy Commission and the National Organization for Medicines. Today, BIOKOSMOS S.A. manufactures and delivers radiopharmaceuticals on a daily basis, including next-day orders, and has expanded its capacity with a second production unit in Northern Greece. Its research activities focus on the development of novel radioactive molecular agents, including the so-called “theranostic pairs of radiopharmaceuticals,” which combine diagnostic and therapeutic functions.
Within the IFIGENEIA project, BIOKOSMOS S.A. will lead Task 4.1, focusing on the development of laboratory conditions and radiation protection frameworks required for the safe and effective production of isotopes. Through this role, the company contributes its extensive technical know-how and regulatory expertise to ensure high safety standards and operational excellence across the project.
